Jagsonpal Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Jagsonpal Pharmaceuticals Ltd trades at ₹231, in a confirmed uptrend and 7 weeks into that stage. That is +10.6% against its own 200-day average. It sits at 85% of a 52-week range of ₹164 to ₹243. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks.

Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹231 it trades +10.6% versus its 200-day average and sits at 85% of its 52-week range (₹164–₹243).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +1,389% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 23 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Jagsonpal Pharmaceuticals Ltd trades at 32.4× P/E, mid-range by its own standards (54th percentile). Its long-run median P/E is 31.1×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 32.4× is mid-range by its own standards (54th percentile), against a long-run median of 31.1× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −22.9% against a −14.9% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +26.3%/yr price move, ~+22.2%/yr came from earnings growth and ~+4.1 pp from the multiple (expanding); over 10y, of the +31.2%/yr price move, ~+29.8%/yr came from earnings growth and ~+1.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Jagsonpal Pharmaceuticals Ltd reads as topping out on its fundamental arc. Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +29.3% at its peak → +3.2% latest) while ROCE still reads 23.0%. The read is built from 8 quarters across 4 curves, on partial evidence.

Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

56.9/100 — rank 4 of 14 in Pharma - API · 81% evidence confidence

Jagsonpal Pharmaceuticals Ltd scores 56.9 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 15.7 + 18.2 + 11.2 + 11.8 = 56.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Jagsonpal Pharmaceuticals Ltd reported ₹82.0 Cr of revenue in the Jun 26 quarter, +7.9% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 7.2% a year. The last full year, FY26, came in at ₹287 Cr. The last four reported quarters add to ₹293 Cr.

FY26 revenue came in at ₹287 Cr (+6.7% on the year), capping 10 years at 7.2% compound. The latest quarter (Jun 26) printed ₹82.0 Cr, +7.9% year on year — the 2nd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +3.4% growth against the decade's 7.2% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +3.2% over the last 4 quarters against +18.4%/yr over the last 8 — rolling over; TTM profit −24.6% vs +51.7%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Jagsonpal Pharmaceuticals Ltd's operating margin is 21.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged −9.0% to 20.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 21.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −9.0%–20.0%, and FY26's 20.0% is the top of that band — a record year.

Why the margin moved: operating margin went +2.2 pp year on year while gross margin went +0.8 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Jagsonpal Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Jun 26 quarter, +18.2% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹43.0 Cr. The 10-year compound rate is 30.5%. That is 15.9% of the quarter's revenue. The same quarter a year earlier earned ₹11.0 Cr.

Jun 26 profit was ₹13.0 Cr, +18.2% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹43.0 Cr (−21.8%), and the 10-year compound rate is 30.5%.

Why profit moved: revenue contributed +7.9% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit −0.1% vs revenue +3.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 114% of Jagsonpal Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹47.0 Cr of operating cash against ₹43.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹47.0 Cr was left as free cash.

FY26: operating cash of ₹47.0 Cr against reported profit of ₹43.0 Cr, leaving free cash of ₹47.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 114% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 114%: the cash cycle tightened 44 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 4.2× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Jagsonpal Pharmaceuticals Ltd's cash conversion cycle runs 33 days in FY26, down from 77 days in FY21. Capital spending ran ₹80.0 Cr over the last 3 years. At FY26 sales of ₹287 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹26.0 Cr sits inside the business at any moment.

FY26: debtors at 22 days, inventory at 51 days — roughly 1.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 33 days, tighter than FY21's 77.

The full loop: cash goes out to suppliers and production on day 0; stock waits 51 days to sell; customers pay about 22 days after that; and suppliers themselves are paid at 40 days — netting out to the 33-day cycle.

In money terms: at FY26 sales of ₹287 Cr, each day of the cycle holds about ₹0.8 Cr — so the 33-day loop keeps roughly ₹26.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹80.0 Cr over the last 3 fiscal years against ₹19.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Jagsonpal Pharmaceuticals Ltd earns a ROCE of 23% in FY26. That is up from a trough of −10% in FY18. Return on invested capital clears the cost of that capital by +9.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.0% net margin on 0.91× asset turns.

FY26 ROCE is 23%, recovered from a FY18 trough of −10% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 15.0% net margin × 0.91× asset turns × 1.15× balance-sheet leverage ≈ 15.7% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 21.8% − 12.0% = a +9.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Jagsonpal Pharmaceuticals Ltd carries total debt of ₹8.0 Cr against shareholder equity of ₹276 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.04 in FY23 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹8.0 Cr against shareholder equity of ₹276 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.04 (FY23) to 0.03 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 1.2 points of Jagsonpal Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 2.3% of the company. Promoters moved +1.0 points over the same window, to 69.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +1.2 points over 8 quarters to 2.3%; Promoters: +1.0 points over 8 quarters to 69.1%; Domestic institutions: −0.2 points over 8 quarters to 0.6%.

Why the register moved: foreign institutions drove it (+1.2 points), alongside promoters (+1.0 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Jagsonpal Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions